Clinical Trial Update: Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

View source ↗

Summary

Expanded access protocol update for Niraparib in patients with recurrent ovarian cancer, sponsored by Tesaro, Inc. The document notes the program status and acc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Recurrent Ovarian Cancer | Status: APPROVED_FOR_MARKETING